


The Region's Only Provider of the
WATCHMAN™
Left Atrial
Appendage Closure
Device Procedure



The Heart Hospital's Structural Heart Program is pleased to offer the implant-based WATCHMAN™ Left Atrial Appendage (LAA) Closure Device procedure. This minimally invasive procedure provides an alternative treatment to long-term anticoagulants for the prevention of stroke in patients with non-valvular atrial fibrillation.

INDICATIONS FOR USE

The WATCHMAN™ Device is indicated to reduce the risk of thromboembolism from the LAA in patients with non-valvular atrial fibrillation who:

- ▶ Are at an increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy,
- ▶ Are deemed to be suitable for short-term (at least 45 days), but not long-term, warfarin therapy, and
- ▶ Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.

(Source: Boston Scientific, 2015)

WHAT TO EXPECT

- ▶ Implantation is performed as an inpatient procedure and under general anesthesia.
- ▶ It takes about an hour to complete the procedure, which requires transfemoral access and transseptal puncture.
- ▶ The patient requires an overnight stay in the hospital (24 hours), and follow-up office visits are required.
- ▶ Following the procedure, the patient stays on warfarin for a minimum of 45 days (until endothelialization of the device).
- ▶ When warfarin ceases, clopidogrel is initiated for six months, and the patient remains on aspirin indefinitely.

OUR EXPERT PHYSICIAN TEAM



The Heart Hospital's WATCHMAN™ implant team includes echocardiographers, interventional cardiologists, cardiac electrophysiologists, cardiac surgeons and anesthesiologists.

If you have questions, call our structural heart coordinator, Cynthia Ansbro, at 812-842-4509 or e-mail cynthia.ansbro@deaconess.com.

The WATCHMAN™ LAAC device is the most studied LAAC device in the world and is the only device with long-term data from both randomized trials and multi-center registries.

COMPARABLE STROKE RISK REDUCTION

The WATCHMAN™ device provided patients with comparable overall protection against all-cause stroke and statistically superior reductions in cardiovascular death and major bleeding compared to warfarin.



ENABLES PATIENTS TO STOP TAKING WARFARIN

The WATCHMAN™ device allowed the vast majority of patients to stop taking warfarin after 45 days to one year.

